217 related articles for article (PubMed ID: 24424155)
1. Non-invasive fecal metabonomic detection of colorectal cancer.
Phua LC; Chue XP; Koh PK; Cheah PY; Ho HK; Chan EC
Cancer Biol Ther; 2014 Apr; 15(4):389-97. PubMed ID: 24424155
[TBL] [Abstract][Full Text] [Related]
2. Global gas chromatography/time-of-flight mass spectrometry (GC/TOFMS)-based metabonomic profiling of lyophilized human feces.
Phua LC; Koh PK; Cheah PY; Ho HK; Chan EC
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Oct; 937():103-13. PubMed ID: 24029555
[TBL] [Abstract][Full Text] [Related]
3. [Proton nuclear magnetic resonance spectroscopy recognition of metabolic patterns in fecal extracts for early diagnosis of colorectal cancer].
Lin Y; Wang ZN; Ma CC; Liu CK; Yang JR; Shen ZW; Wu RH
Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Sep; 50(9):788-793. PubMed ID: 27655598
[No Abstract] [Full Text] [Related]
4. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS).
Chan EC; Koh PK; Mal M; Cheah PY; Eu KW; Backshall A; Cavill R; Nicholson JK; Keun HC
J Proteome Res; 2009 Jan; 8(1):352-61. PubMed ID: 19063642
[TBL] [Abstract][Full Text] [Related]
5. Urinary metabonomic study on colorectal cancer.
Qiu Y; Cai G; Su M; Chen T; Liu Y; Xu Y; Ni Y; Zhao A; Cai S; Xu LX; Jia W
J Proteome Res; 2010 Mar; 9(3):1627-34. PubMed ID: 20121166
[TBL] [Abstract][Full Text] [Related]
6. Fecal Fatty Acid Profiling as a Potential New Screening Biomarker in Patients with Colorectal Cancer.
Song EM; Byeon JS; Lee SM; Yoo HJ; Kim SJ; Lee SH; Chang K; Hwang SW; Yang DH; Jeong JY
Dig Dis Sci; 2018 May; 63(5):1229-1236. PubMed ID: 29516324
[TBL] [Abstract][Full Text] [Related]
7. Metabonomics identifies serum metabolite markers of colorectal cancer.
Tan B; Qiu Y; Zou X; Chen T; Xie G; Cheng Y; Dong T; Zhao L; Feng B; Hu X; Xu LX; Zhao A; Zhang M; Cai G; Cai S; Zhou Z; Zheng M; Zhang Y; Jia W
J Proteome Res; 2013 Jun; 12(6):3000-9. PubMed ID: 23675754
[TBL] [Abstract][Full Text] [Related]
8. NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer.
Lin Y; Ma C; Liu C; Wang Z; Yang J; Liu X; Shen Z; Wu R
Oncotarget; 2016 May; 7(20):29454-64. PubMed ID: 27107423
[TBL] [Abstract][Full Text] [Related]
9. A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics.
Farshidfar F; Weljie AM; Kopciuk KA; Hilsden R; McGregor SE; Buie WD; MacLean A; Vogel HJ; Bathe OF
Br J Cancer; 2016 Sep; 115(7):848-57. PubMed ID: 27560555
[TBL] [Abstract][Full Text] [Related]
10. Metabotyping of human colorectal cancer using two-dimensional gas chromatography mass spectrometry.
Mal M; Koh PK; Cheah PY; Chan EC
Anal Bioanal Chem; 2012 Apr; 403(2):483-93. PubMed ID: 22374317
[TBL] [Abstract][Full Text] [Related]
11.
Lin Y; Ma C; Bezabeh T; Wang Z; Liang J; Huang Y; Zhao J; Liu X; Ye W; Tang W; Ouyang T; Wu R
Int J Cancer; 2019 Sep; 145(6):1679-1689. PubMed ID: 30720869
[TBL] [Abstract][Full Text] [Related]
12. Specificity of metabolic colorectal cancer biomarkers in serum through effect size.
Di Giovanni N; Meuwis MA; Louis E; Focant JF
Metabolomics; 2020 Aug; 16(8):88. PubMed ID: 32789702
[TBL] [Abstract][Full Text] [Related]
13. A quantitative multimodal metabolomic assay for colorectal cancer.
Farshidfar F; Kopciuk KA; Hilsden R; McGregor SE; Mazurak VC; Buie WD; MacLean A; Vogel HJ; Bathe OF
BMC Cancer; 2018 Jan; 18(1):26. PubMed ID: 29301511
[TBL] [Abstract][Full Text] [Related]
14. Distinct urinary metabolic profile of human colorectal cancer.
Cheng Y; Xie G; Chen T; Qiu Y; Zou X; Zheng M; Tan B; Feng B; Dong T; He P; Zhao L; Zhao A; Xu LX; Zhang Y; Jia W
J Proteome Res; 2012 Feb; 11(2):1354-63. PubMed ID: 22148915
[TBL] [Abstract][Full Text] [Related]
15. Electronic nose can discriminate colorectal carcinoma and advanced adenomas by fecal volatile biomarker analysis: proof of principle study.
de Meij TG; Larbi IB; van der Schee MP; Lentferink YE; Paff T; Terhaar Sive Droste JS; Mulder CJ; van Bodegraven AA; de Boer NK
Int J Cancer; 2014 Mar; 134(5):1132-8. PubMed ID: 23959518
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive urinary metabonomic diagnosis of human bladder cancer.
Pasikanti KK; Esuvaranathan K; Ho PC; Mahendran R; Kamaraj R; Wu QH; Chiong E; Chan EC
J Proteome Res; 2010 Jun; 9(6):2988-95. PubMed ID: 20337499
[TBL] [Abstract][Full Text] [Related]
17. Metabolomic Profiling Identified Serum Metabolite Biomarkers and Related Metabolic Pathways of Colorectal Cancer.
Zhang C; Zhou S; Chang H; Zhuang F; Shi Y; Chang L; Ai W; Du J; Liu W; Liu H; Zhou X; Wang Z; Hong T
Dis Markers; 2021; 2021():6858809. PubMed ID: 34917201
[TBL] [Abstract][Full Text] [Related]
18. Urine-NMR metabolomics for screening of advanced colorectal adenoma and early stage colorectal cancer.
Kim ER; Kwon HN; Nam H; Kim JJ; Park S; Kim YH
Sci Rep; 2019 Mar; 9(1):4786. PubMed ID: 30886205
[TBL] [Abstract][Full Text] [Related]
19. 1H HR-MAS NMR spectroscopy of tumor-induced local metabolic "field-effects" enables colorectal cancer staging and prognostication.
Jiménez B; Mirnezami R; Kinross J; Cloarec O; Keun HC; Holmes E; Goldin RD; Ziprin P; Darzi A; Nicholson JK
J Proteome Res; 2013 Feb; 12(2):959-68. PubMed ID: 23240862
[TBL] [Abstract][Full Text] [Related]
20. Identification of differential metabolic characteristics between tumor and normal tissue from colorectal cancer patients by gas chromatography-mass spectrometry.
Ning W; Li H; Meng F; Cheng J; Song X; Zhang G; Wang W; Wu S; Fang J; Ma K; Yang J; Pei D; Dong F
Biomed Chromatogr; 2017 Nov; 31(11):. PubMed ID: 28475217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
